anti-VEGF

Anti-VEGF PBS drug

Anti-VEGF remains most expensive PBS drug

The Australian government spent $55 million more on anti-VEGF macular disease therapies in 2020-21 compared to the previous year, with aflibercept (Eylea) maintaining its title as the costliest subsided drug in the country.
Read More
Novartis ophthalmology sale

Novartis secures PBS recommendation for Beovu

An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment.
Read More

Ophthalmology’s most life-changing procedures revealed

Seventy-five percent of ophthalmic interventions investigated in a major study have shown evidence of improving quality of life for patients with eye disease, with cataract surgery and anti-VEGF therapy singled out as some of the most important procedures.
Read More

Anti-VEGF becomes most expensive drug on PBS

The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a hepatitis C drug to become the costliest subsidised drug for the first time.  
Read More

Eylea biosimilar embarks on Phase 3 trial

A biopharmaceutical company that is developing cheaper anti-VEGF treatments for Australia and other markets has launched a global clinical trial for a biosimilar version of leading treatment Eylea (aflibercept).
Read More

Traces of anti-VEGF drugs found in breast milk

Anti-vascular endothelial growth factor (anti-VEGF) drugs have been identified in breast milk, prompting warnings from the researchers that the use of these medications during breastfeeding could affect developing infants.
Read More